References
- Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006841. doi: 10.1101/cshperspect.a006841
- HIV who.int: World Health Organization. 2023 [cited 2023 sep 4]. Available from: https://www.who.int/data/gho/data/themes/hiv-aids#:~:text=Globally%2C%2039.0%20million%20%5B33.1–,considerably%20between%20countries%20and%20regions.
- UNAIDS. Prevailing against pandemics: by putting people at the centre | world AIDS day Report 2020. UNAIDS.org: United Nations; 2020.
- Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014 Sep;28(3):371–402. doi: 10.1016/j.idc.2014.06.001
- Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med. 1987;317(4):185–191. doi: 10.1056/NEJM198707233170401
- FDA Approves New HIV Drug for Adults with Limited Treatment Options [Internet]. FDA.gov: FDA. [updated 2022 Dec 22], [cited 2023 Sep 4]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-hiv-drug-adults-limited-treatment-options#:~:text=Sunlenca%20is%20the%20first%20of,approved%20for%20treating%20HIV%2D1.
- Sulenca (R) [package insert] Gilead Sciences. Foster City CA: Inc; 2022.
- Study to compare bictegravir/lenacapavir versus current therapy in people with hiv-1 who are successfully treated with a complicated regimen.
- Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023 Oct 01;21(10):657–670.
- Duncombe C, Ravishankar S, Zuniga JM. Fast-track cities: striving to end urban HIV epidemics by 2030. Curr Opin HIV AIDS. 2019;14(6):503–508. doi: 10.1097/COH.0000000000000583
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department Of Health And Human Services. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
- Global HIV treatment Market analysis Report 2023: a $25+ Billion Market by 2030 - Focus on combination therapies Gaining Momentum - ResearchAndMarkets.com 2023 [cited 2023 Sep 29]. Available from: https://www.businesswire.com/news/home/20230629675173/en/Global-HIV-Treatment-Market-Analysis-Report-2023-A-25-Billion-Market-by-2030—Focus-on-Combination-Therapies-Gaining-Momentum—ResearchAndMarkets.com
- Chun HM, Dirlikov E, Cox MH, et al. Vital signs: progress toward eliminating HIV as a global public health threat through scale-up of antiretroviral therapy and health system strengthening supported by the US president’s emergency plan for AIDS relief—worldwide, 2004–2022. Morbidity Mortality Weekly Rep. 2023;72(12):317. doi: 10.15585/mmwr.mm7212e1
- White KL, Osman N, Cuadra-Foy E, et al. Long dissociation of bictegravir from HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2023 May 1;65(5). doi: 10.1128/AAC.02406-20
- Biktarvy (R) [package insert] Gilead Sciences. Foster City CA: Inc; 2022.
- Link JO, Rhee MS, Tse WC. et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020 Aug;584(7822):614–618.
- Sunlenca: European Unions Agencies Network; 2023 [updated, 2023 Jun 27; cited 2023 Aug 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/sunlenca
- Zhang H, Custodio J, Wei X, et al. P176 clinical pharmacology of the HIV integrase strand transfer inhibitor bictegravir. Sex Transm Infect. 2017;93(Suppl 1):A74–A74.
- Podany AT, Scarsi KK, Pham MM, et al. Comparative clinical pharmacokinetics and pharmacodynamics of HIV-1 integrase strand transfer inhibitors: an updated review. Clin Pharmacokinet. 2020;59(9):1085–1107. doi: 10.1007/s40262-020-00898-8
- Gallant JE, Thompson M, DeJesus E, et al. Antiviral activity, safety, and pharmacokinetics of bictegravir as 10-day monotherapy in HIV-1-Infected adults. J Acquir Immune Defic Syndr. 2017 May 1;75(1):61–66. doi: 10.1097/QAI.0000000000001306
- Paik J. Lenacapavir: First Approval. Drugs. 2022 Sep;82(14):1499–1504. doi: 10.1007/s40265-022-01786-0
- Study to evaluate safety, pharmacokinetics, and antiviral activity of bictegravir (GS-9883) in human immunodeficiency virus (HIV)-1 infected participants.
- Sax PE, DeJesus E, Crofoot G. et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017 Apr;4(4):e154–e160.
- Gupta SK, Berhe M, Crofoot G, et al. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. Lancet HIV. 2023 Jan;10(1):e15–e23. doi: 10.1016/S2352-3018(22)00291-0
- Hagins D, Safran R, Santiago L, et al., editors. Long-acting Lenacapavir in a combination regimen for treatment naive PWH: week 80 CROI. Seattle WA; 2023.
- Segal-Maurer S, DeJesus E, Stellbrink HJ, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022 May 12;386(19):1793–1803. doi: 10.1056/NEJMoa2115542
- Center for Drug evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. In Research CfDEa. Silver Spring MD: HHS; 2015.
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen Clinicaltrials.gov: NIH National Library of Medicine 2022 [cited 2023 Oct 9]. Available from: https://classic.clinicaltrials.gov/ct2/show/record/NCT05502341?view=record
- Bester SM, Wei G, Zhao H, et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science. 2020;370(6514):360–364. doi: 10.1126/science.abb4808
- Study of Lenacapavir for HIV pre-exposure prophylaxis in people who are at risk for HIV infection (PURPOSE 2) Clinicaltrials.Gov2022. [cited 2023 Jan 9]. Available from: https://clinicaltrials.gov/study/NCT04925752
- Subramanian R, Wang J, Murray B, et al. Human pharmacokinetics prediction with an in vitro-in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy(®) for the treatment of HIV-1 infection. Xenobiotica. 2022 Dec;52(12):1020–1030.
- Biktarvy [Website]. European medicines Agency: European Union agencies network. 2023 [updated 2023 Apr 28; cited 2023 Aug 19]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy#authorisation-details-section
- Study to compare bictegravir/Lenacapavir versus Current therapy in people with HIV-1 who are successfully treated with a complicated regimen [updated January]. Available from: https://classic.clinicaltrials.gov/show/NCT05502341
- Martin M, Del Cacho E, Codina C, et al. Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Human Retroviruses. 2008;24(10):1263–1268. doi: 10.1089/aid.2008.0141
- Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol. 2015;10(11):1773–1782. doi: 10.2217/fmb.15.106
- Lesho EP, Gey DC. Managing issues related to antiretroviral therapy. Am Fam Physician. 2003;68(4):675–687.
- Dvory-Sobol H, Shaik N, Callebaut C, et al. Lenacapavir: a first-in-class HIV-1 capsid inhibitor. Curr Opin HIV AIDS. 2022;17(1):15–21. doi: 10.1097/COH.0000000000000713
- Teeraananchai S, Kerr S, Amin J, et al. Life expectancy of HIV‐positive people after starting combination antiretroviral therapy: a meta‐analysis. HIV Med. 2017;18(4):256–266. doi: 10.1111/hiv.12421
- Margot N, Ram R, Rhee M, et al. Absence of lenacapavir (GS-6207) phenotypic resistance in HIV gag cleavage site mutants and in isolates with resistance to existing drug classes. Antimicrob Agents Chemother. 2021;65(3):10.1128/aac.02057–20. doi: 10.1128/AAC.02057-20
- Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012;72(9):e1–e25. doi: 10.2165/11633630-000000000-00000
- Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(17):1817–1828. doi: 10.1007/s40265-018-1010-7
- Holec AD, Mandal S, Prathipati PK, et al. Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. Curr HIV Res. 2017;15(6):411–421. doi: 10.2174/1570162X15666171120110145
- Santevecchi BA, Miller S, Childs-Kean LM. Doing more with less: review of dolutegravir-lamivudine, a novel single-tablet regimen for antiretroviral-naïve adults with HIV-1 infection. Ann Pharmacother. 2020;54(12):1252–1259. doi: 10.1177/1060028020933772